Log in

NASDAQ:TMDXTransMedics Group Stock Price, Forecast & News

$17.43
+0.01 (+0.06 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.19
Now: $17.43
$17.73
50-Day Range
$13.08
MA: $15.76
$17.92
52-Week Range
$10.10
Now: $17.43
$27.42
Volume85,200 shs
Average Volume215,051 shs
Market Capitalization$372.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2
TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TMDX
CUSIPN/A
CIKN/A
Phone978-552-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.60 million
Book Value$2.58 per share

Profitability

Net Income$-33,550,000.00
Net Margins-134.19%

Miscellaneous

EmployeesN/A
Market Cap$372.30 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

How has TransMedics Group's stock been impacted by COVID-19 (Coronavirus)?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TMDX stock has increased by 28.0% and is now trading at $17.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TransMedics Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TransMedics Group.

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransMedics Group.

How were TransMedics Group's earnings last quarter?

TransMedics Group Inc (NASDAQ:TMDX) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $7.53 million for the quarter, compared to analyst estimates of $7.49 million. TransMedics Group had a negative net margin of 134.19% and a negative return on equity of 60.19%. View TransMedics Group's earnings history.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.4-7.5 million, compared to the consensus revenue estimate of $6.87 million.

What price target have analysts set for TMDX?

4 brokerages have issued 12-month price targets for TransMedics Group's shares. Their forecasts range from $16.00 to $28.00. On average, they expect TransMedics Group's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price. View analysts' price targets for TransMedics Group.

Has TransMedics Group been receiving favorable news coverage?

Press coverage about TMDX stock has trended negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TransMedics Group earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about TransMedics Group.

Are investors shorting TransMedics Group?

TransMedics Group saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,080,000 shares, a decline of 46.5% from the June 15th total of 2,020,000 shares. Based on an average trading volume of 166,200 shares, the short-interest ratio is presently 6.5 days. Currently, 5.4% of the shares of the company are sold short. View TransMedics Group's Current Options Chain.

Who are some of TransMedics Group's key competitors?

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Gilead Sciences (GILD), Roku (ROKU), AT&T (T), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Beyond Meat (BYND), Walt Disney (DIS) and Etsy (ETSY).

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
  • Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
  • Mr. John F. Carey, VP of Operations (Age 55)
  • Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
  • Mr. Brian Thomson, VP of HR (Age 51)

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $17.43.

How big of a company is TransMedics Group?

TransMedics Group has a market capitalization of $372.30 million and generates $23.60 million in revenue each year. The company earns $-33,550,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at 978-552-0900 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.